LGD-2226

Selective Androgen Receptor Agonism#

LGD-2226 is a nonsteroidal, full agonist at the androgen receptor (AR) built on a fluorinated quinolin-2-one scaffold. The defining pharmacology is selectivity — high binding affinity at AR with essentially no measurable activity at glucocorticoid, progesterone, mineralocorticoid, or estrogen receptors. This is what distinguishes it from testosterone and the classical 19-nor AAS, which engage multiple nuclear receptors and produce broad off-target effects.

"A novel, nonsteroidal quinolone structure produced a potent, orally active SARM with high AR selectivity, negligible affinity for other nuclear receptors, and favorable oral bioavailability in rodents." — van Oeveren A, Motamedi M, Mani NS, et al., Journal of Medicinal Chemistry (2006)

Practically, this clean receptor profile is the reason LGD-2226 doesn't carry estrogenic side effects (gyno, water retention) or mineralocorticoid issues (blood pressure surges from sodium retention) the way wet AAS do.

Tissue-Selective Coactivator Recruitment#

The "selective" half of SARM refers to differential conformational change at the AR ligand-binding domain depending on tissue context. LGD-2226 binds AR in a way that recruits the coactivator complexes present in skeletal muscle and bone — driving full anabolic transcription — while failing to fully recruit the coactivators that mediate prostatic growth. The result is a strongly dissociated anabolic/androgenic profile: a roughly 200:50 anabolic-to-androgenic ratio in preclinical assays.

"LGD2226 restored muscle mass and function in orchiectomized rats, improved bone strength and mineral density, but produced only minimal increases in prostate weight even at maximal anabolic doses." — Miner JN, Chang W, Chapman MS, et al., Endocrinology (2007)

"SARMs such as LGD-2226 demonstrate tissue selectivity with the ability to promote anabolic effects in muscle and bone while limiting activity in androgen-sensitive tissues." — Gao W, Dalton JT, Drug Discovery Today (2007)

For physique-focused users, the translation is muscle accrual at doses that should be substantially less prostate-active than equivalent AAS — though "less" in rodents is not "none" in humans, and PSA monitoring is still on the table.

No Aromatization, No 5α-Reduction#

LGD-2226 is not a substrate for aromatase or 5α-reductase. The trifluoromethyl-substituted quinolinone core is not recognized by either enzyme, so there is no estradiol conversion and no DHT metabolite generated downstream.

"LGD-2226 exerts its anabolic effects via selective androgen receptor activation, with no aromatization or 5α-reduction, and represents a next-generation SARM scaffold." — Bhasin S, Jasuja R., Current Opinion in Clinical Nutrition and Metabolic Care (2009)

Two consequences fall out of this:

1. No AI required on cycle. Estrogen-mediated side effects (gyno, estrogenic bloat) are off the table from LGD-2226 itself. The flip side — no estrogen at all when endogenous testosterone is suppressed — means joint comfort, libido, and mood can dip on longer blocks, which is one of the arguments for keeping cycles bounded at 8 weeks.
2. Hairline impact is parent-compound, not DHT-driven. Because there's no 5α-reduction step, oral 5-AR inhibitors (finasteride, dutasteride) don't blunt LGD-2226's scalp effects. Users running it inside a hair stack rely on topical AR antagonists (RU58841, pyrilutamide) for follicular protection, not finasteride.

Bone-Anabolic Action#

LGD-2226's strongest signal in the preclinical record — stronger than its muscle data, in some ways — is on bone. In orchiectomized rats it restored trabecular and cortical bone mineral density and improved biomechanical strength on three-point bending tests. AR is expressed in osteoblasts and osteocytes; full agonism there drives osteoblast differentiation and suppresses osteoclast-mediated resorption, which is the basis of the bone phenotype.

This matters most for two physique-focused use cases: users coming off long, heavily suppressive AAS cycles where bone turnover has been disturbed, and older recomp-focused users whose baseline DEXA bone density is trending the wrong way.

Preserved Sexual Reflex, Reduced LH Suppression#

Unlike some earlier "muscle-only" SARM candidates that abolished CNS-mediated sexual function in rodent models, LGD-2226 retained erectile/sexual reflex behaviour in orchiectomized rats and produced less LH suppression than testosterone at equi-anabolic doses. The mechanism is thought to involve weaker negative feedback at the hypothalamic-pituitary level relative to the muscle/bone agonism — the dissociation extends to the HPTA, not just the prostate.

In practical terms: suppression on cycle is real and SERM-based PCT is still appropriate after 8-week blocks, but the depth of suppression is expected to be milder than what comparable AAS doses produce.

Detection and Doping Context#

For anyone in tested sport, the mechanism story matters less than the analytical story: LGD-2226 and its hydroxylated metabolites are detectable by validated LC-MS/MS urinary assays and have been on the WADA prohibited list since 2008.

"Following LGD-2226 administration in rats, several urinary metabolites were identified, supporting the ability to detect this compound in anti-doping testing settings." — Thevis M, Kohler M, Schlörer N, et al., Rapid Communications in Mass Spectrometry (2008)

The trifluoroethyl groups that make the parent compound metabolically stable also produce distinctive fluorinated metabolites with long detection tails — useful to know if competition timing is a consideration.

Common (most users)#

• HPTA suppression — expected on any 8-week+ block. LH/FSH knock-down is documented in ORX rats at anabolically equivalent doses, though less severe than testosterone itself. Mitigation: cap blocks at 8 weeks, run a SERM-based PCT (enclomiphene 12.5mg/day or tamoxifen 20mg/day × 4 weeks), confirm recovery with bloodwork 4–6 weeks post-PCT.
• HDL suppression / lipid drift — class effect for nonsteroidal SARMs in this scaffold family. Mitigation: baseline lipid panel, repeat at week 4 and week 8. Cardio 3×/week, citrus bergamot 1g/day, and a low-saturated-fat dietary baseline blunt the shift. If HDL drops below 25 mg/dL on cycle, dose reduction is the protocol.
• Mild transaminase elevation — ALT/AST creep is the modal liver finding across the SARM class. Mitigation: TUDCA 500mg/day, no concurrent alcohol or hepatotoxic orals (winstrol, anavar, superdrol), and a mid-cycle LFT panel.
• Mild lethargy or "flat" mood in week 1–2 — typical as endogenous androgen production starts to fall. Usually self-resolves; if persistent at week 4, suppression is deeper than expected and a SERM bridge is warranted.

Uncommon (dose-dependent or individual)#

• Scalp shedding / accelerated hair miniaturization in genetically predisposed users. The rodent prostate-sparing profile does not translate to a hair-sparing profile in humans — AR activation in dermal papilla is dermal papilla. Mitigation: topical finasteride 0.25% or oral 0.5–1mg/day in AR-sensitive users; pyrilutamide or RU58841 for those avoiding systemic 5-AR inhibition.
• Sebum elevation, acne flares — AR-driven sebaceous activity. Mitigation: salicylic/benzoyl peroxide regimen, adapalene 0.1%, dose reduction if breakout is severe.
• Blood pressure creep — secondary to lipid shift and mild fluid retention. Mitigation: check BP weekly; telmisartan 20–40mg/day is the community default if systolic drifts above 135.
• Hematocrit elevation — less pronounced than with testosterone but possible at advanced doses (10–15mg/day). Check CBC mid-cycle; donate blood if HCT >52%.
• PSA elevation — modest in rodents but worth tracking in users over 35 or with family history. Baseline + end-cycle PSA is appropriate.

Rare but serious#

• Significant hepatotoxicity (ALT/AST >3× ULN, jaundice, RUQ pain) — rare at community doses but documented across the SARM class. Discontinue immediately and confirm with repeat LFTs and bilirubin.
• Severe dyslipidemia (HDL <20, apoB >100 in a previously normal user) — discontinue, allow 8–12 weeks recovery, recheck before considering another cycle.
• Cardiovascular events — no LGD-2226-specific case reports exist (the human footprint is too small), but the broader nonsteroidal SARM literature includes isolated reports of cardiomyopathy and thrombotic events in users running multi-compound stacks. Warning signs: exertional dyspnea, chest pain, palpitations, unilateral leg swelling. These warrant immediate cessation and ECG/echo workup.
• Persistent post-cycle hypogonadism — clinical low-T symptoms (libido, mood, morning erections, energy) still present 12 weeks post-PCT. Bloodwork (LH, FSH, total/free T) confirms; HCG mono or restart-protocol management is the path forward.

Hard contraindications#

• Pregnancy or pregnancy potential — AR agonism virilizes a female fetus. Non-aromatizable does not mean non-androgenic. Absolute contraindication.
• Active or prior androgen-sensitive malignancy (prostate, certain breast subtypes) — AR activation is contraindicated.
• Untreated hypertension or baseline dyslipidemia — class lipid and pressure effects stack on top of an already compromised baseline.
• Baseline hepatic dysfunction — elevated transaminases, fatty liver disease, or recent hepatotoxic exposure (oral AAS, isotretinoin within 30 days, heavy alcohol). The compound clears hepatically; a compromised liver is a hard stop.
• Tested athletic competition — WADA-banned since 2008. Parent compound and hydroxylated urinary metabolites are detectable by validated LC-MS/MS assays.

"Following LGD-2226 administration in rats, several urinary metabolites were identified, supporting the ability to detect this compound in anti-doping testing settings." — Thevis et al., Rapid Commun Mass Spectrom (2008)

• Concurrent stack with multiple hepatotoxic orals (17α-alkylated AAS + LGD-2226 + isotretinoin, for example) without a clean liver baseline and active monitoring.

Gender and PCT considerations#

LGD-2226 is not appropriate for female subjects. Virilization risk — voice deepening (often irreversible), clitoral enlargement, hair-pattern shift, menstrual disruption — applies to any AR full agonist, regardless of how prostate-sparing the rodent data look. The dissociation index in Miner 2007 is muscle-vs-prostate, not muscle-vs-female-secondary-sex-tissue.

"LGD2226 restored muscle mass and function in orchiectomized rats, improved bone strength and mineral density, but produced only minimal increases in prostate weight even at maximal anabolic doses." — Miner et al., Endocrinology (2007)

For male subjects, PCT is required after any 8-week block at community doses (5–10mg/day). Standard SERM protocols apply:

No AI is required — LGD-2226 does not aromatize, so estradiol management is not part of the protocol. Confirm recovery with a full hormone panel (LH, FSH, total/free T, E2, SHBG) 4–6 weeks after PCT completion before considering the next block.

Where multi-LGD blends are sourced (LGD-4033 + LGD-3303 + LGD-2226 in fixed ratios), the suppression and lipid burden are driven by the sum of the components, not LGD-2226 alone — treat the stack as a heavier-than-LGD-4033-mono cycle for PCT and bloodwork planning.